Multidisciplinary Cancer Teams Lack Information on Patients' Comborbidity

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Annals of Oncology, researchers in New Zealand have found that multidisciplinary cancer team meetings need to systematically consider treatment of patients with comorbidity in order to improve outcomes of patients with cancer with comorbidities.

For the study, researchers sought to investigate how comorbidity of patients with cancer is considered in multidisciplinary cancer team meetings, and how information on comorbidity impacts decision-making. Researchers conducted a systematic literature review to evaluate previous research on consideration and impact of comorbidity in multidisciplinary cancer team decision-making of their patients' treatments. They identified 21 studies for the review.

Results showed that lack of information on patients' comorbidity in team meetings affect the ability of team members to make therapy recommendations and decreases the likelihood that those recommendations are implemented in patients with comorbidity.

In addition, researchers found that when treatment for those with comorbidity is different than from what is recommended, it is more conservative even though the recommended treatment may be effective and tolerated. Researchers also found that team members are likely unaware that they are ignoring comborbidity issues.

The authors conclude that multidisciplinary team members should systematically consider treatment options for patients with cancer and comorbidity in order to enhance decision-making.

Prostate biopsy
Multidisciplinary cancer team meetings need to systematically consider treatment of patients with comorbidity.
Comorbidity is very common among patients with cancer. Multidisciplinary team meetings (MDTs) are increasingly the context within which cancer treatment decisions are made internationally. Little is known about how comorbidity is considered, or impacts decisions, in MDTs. MDTs should systematically consider treatment of patients with comorbidity.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs